Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs

Artios Pharma Limited, a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, led by Michael T. Andriole, Christine Silverstein, Graeme Smith, Ian Smith, and others, has announced the successful close of an oversubscribed $115 million Series D financing, co-led by founding investor SV Health Investors and new investor RA Capital Management, with participation from new investor Janus Henderson Investors and broad support from Artios’ existing investors. The investors who supported the Series D round include Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henderson Investors, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, RA Capital Management, Sofinnova Partners, Schroders Capital, and SV Health Investors.

Series D funding will expand clinical evaluation of alnodesertib in ATM-negative pancreatic and colorectal cancer. The program recently received FDA Fast Track status, and trial data showed a 50% confirmed response rate in ATM-negative solid tumors. With no approved treatments for ATM deficiency, alnodesertib continues to deliver durable responses across multiple tumor types.

Proceeds will also support a Phase 2 randomized trial of ART6043 in BRCA-mutant, HER2-negative breast cancer patients eligible for PARP inhibitors. ART6043, a Polθ inhibitor, has shown good tolerability, expected PK/PD activity, and encouraging early signals in Phase 1/2a data. Artios is additionally advancing a first-in-class DDRi-ADC program and plans to nominate a lead candidate in Q1 2026.

The Series D funding accelerates registration paths for alnodesertib and ART6043, expanding development of next-generation DDR therapies for high-need indications in pancreatic, colorectal, and breast cancer. The round reflects continued support from existing investors and the addition of new backers, strengthening momentum to advance these medicines toward patients.